
News|Articles|July 1, 2009
FDA Pipeline preview, July 2009 (bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, paclitaxel)
Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel
Advertisement
Complete response
Recommended for approval
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transparency paves the way for lower costs and equitable access
2
New self-injectable biologics promise cost savings and patient convenience
3
Evaluating Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease: Written Recap
4
Stanford scientists find link between Epstein-Barr virus and lupus
5






















































